Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Protective Effects of Adipose-derived Stem Cell Exosomes vs Dexamethasone on Neuromotor Deficits in Focal Cerebral Ischemia.

Heydari M., Jalali Kondori B., Raei M., Eftekhari Moghadam AR.

Randomized Controlled Trial on Stroke Research, Chronic Inflammation, published in Basic Clin Neurosci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Basic Clin Neurosci (2025)
Country
Iran
Reported sample size
—
Source database
PubMed
PMID
42220924
PMCID
PMC13220680
DOI
10.32598/bcn.2025.7946.1

Abstract (original English)

Introduction Cerebral ischemia is a leading cause of mortality and long-term disability worldwide, characterized by restricted blood flow to the brain, resulting in inflammation, oxidative stress, and neuronal death. Current therapies, such as thrombolytics and corticosteroids, offer limited efficacy in reversing neuronal damage. Recent advances suggest that exosomes derived from mesenchymal stem cells (MSCs) may provide neuroprotective benefits through anti-inflammatory and regenerative mechanisms. This study aimed to evaluate the therapeutic effects of exosomes derived from adipose tissue-MSCs (AT-MSCs) compared to dexamethasone in a rat model of transient focal cerebral ischemia. Methods Twenty adult male Wistar rats were randomly assigned to four groups: Sham, transient middle cerebral artery occlusion (MCAO) control, exosome-treated, and dexamethasone-treated. MACO was induced to simulate an ischemic stroke. Exosomes were administered intravenously, while dexamethasone was given intraperitoneally. Behavioral assessments (Bederson and Garcia scores), infarct volume (2,3,5-triphenyltetrazolium chloride [TTC] staining), serum inflammatory markers (nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6]), and histopathological changes (H&E and Nissl staining) were analyzed. Results Exosome treatment signific

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research